Bahrain’s GDA holds board of directors meeting

The Gulf Downstream Association (GDA) held its fourth quarterly board of directors meeting at its headquarters in GBCorp Tower, Bahrain Financial Harbor.
Short Url
Updated 26 January 2020

Bahrain’s GDA holds board of directors meeting

The Gulf Downstream Association (GDA) held its fourth quarterly board of directors meeting at its headquarters in GBCorp Tower, Bahrain Financial Harbor. The board of directors went on to attend key sessions of the GDA Annual Single Points of Contact (SPOCs) and Subject Matter Experts (SMEs) Meet at the Wyndham Grand, Manama, which was attended by more than 50 high-level representatives of GDA’s member companies — a mix of regional and international players. 

These include national oil companies of the Gulf region such as Saudi Aramco, Kuwait Petroleum International (KPI), Bahrain Petroleum Company (Bapco), Kuwait National Petroleum Company (KNPC) and Abu Dhabi National Oil Company (ADNOC) Refining, in addition to other global producers.

At the quarterly board meeting, members discussed matters relating to the “GDA International Downstream Conference and Exhibition 2020,” which is scheduled to take place from Oct. 20 to 22 at the Bahrain International Convention and Exhibition Center. Suleman A. Al-Bargan, vice president of domestic refining and NGL fractionation at Saudi Aramco and GDA chairman, along with the other board members congratulated Ebrahim Talib, deputy chief executive — Bapco, on his appointment as the conference chair and Waleed K. Al-Bader, CEO of KNPC, on his appointment as conference co-chair. Additionally, the board also reviewed and approved the budget for 2020.


Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

Updated 27 May 2020

Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

  • Trials are being led locally as an essential means to verify the safety and effectiveness of a new drug
  • Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic

RIYADH: Clinical trials in Saudi Arabia could speed up the adoption of new drugs locally, a pharmaceutical executive has told Arab News.

“Clinical trials have two very big benefits for the Kingdom. Firstly, they provide data in the long run with respect to safety and efficacy, catered specifically to the Saudi population. Secondly, they impact local investment and build healthcare capabilities,” Managing Director of Eli Lilly Dimitri Livadas said..

Lividas further explained that the clinical trial phase of any new treatment is crucial as it represents the stage between the adoption or rejection of a drug. Working with the Ministry of Health and with a presence in the Kingdom for 42 years, the pharmaceutical company began research trials in the country in 2016, consisting of five pre-marketing activities and three monitoring studies for post-marketing.

Lividas added that the trials are being led locally as an essential means to verify the safety and effectiveness of a new drug before it is put to the market and introduced to patients. The majority of these are focused on diabetes, oncology, immunology, and osteoporosis.

“We genuinely believe that our future is here in Saudi Arabia. We continue to make great progress in having a commercial organization in the Kingdom that is fully staffed by Saudi nationals,” said Lividas.

As a biopharmaceutical company, Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic. It recently announced partnership with AbCellera to develop a treatment for the virus and aims to enter into clinical trials this year.

“I salute the Saudi authorities for their strong measures to contain the spread of COVID-19. I think it is an example to the world on how to do this. I would like to also express my gratitude toward all healthcare professionals who are currently on the frontlines, risking their own health to help others," Lividas said.